INTERMACS Levels Playing Field for Mechanical Circulatory Support
INTERMACS is the national registry for patients with FDA-approved mechanical circulatory support (MCS) devices that treat advanced heart failure. This registry was devised as a joint effort of the National Heart, Lung and Blood Institute (NHLBI), the Centers for Medicare and Medicaid Services (CMS) and the Food and Drug Administration (FDA), in conjunction with the University of Alabama at Birmingham (UAB) and United Network for Organ Sharing (UNOS).
By applying uniform definitions and standards, INTERMACS levels the playing field for mechanical circulatory support devices. INTERMACS tracks patient survival, adverse events and cause of death over time by patient profile, device and device category.
This was the last report in which INTERMACS publicly published bridge-to-transplant rates** and patient profile status for left ventricular assist devices (LVADs), biventricular assist devices (BiVADs) and the Total Artificial Heart (TAH).
74% (1089/1476) of all INTERMACS patients were in the two sickest categories.
*90% (46/51) of all Total Artificial Heart patients were in the two sickest categories.
1089-46 = 1043 LVAD/BiVAD patients were in the two sickest categories.
*73% (1043/1425) of LVAD/BiVAD patients were in the two sickest categories.
**Once stable, U.S. Total Artificial Heart patients in the hospital are listed UNOS Status 1A and moved to the top of the transplant list.
Source: UNOS Policy 3.7 - Allocation of Thoracic Organs, pages 1-3
NEXT ›› Compare the TAH to BiVADS